Chris Ryan

WJ01024 alone and in combination with ruxolitinib was safe and generated efficacy signals in relapsed/refractory myelofibrosis.

Nogapendekin alfa inbakicept plus PD-L1 t-haNK and bevacizumab produced encouraging overall survival data in recurrent glioblastoma.

The FDA has granted orphan drug designation to zavabresib for the treatment of patients with myelofibrosis.

Toripalimab and chidamide demonstrated particularly notable efficacy outcomes in well-differentiated liposarcoma and dedifferentiated liposarcoma.

Treatment with an allogeneic CD19-directed CAR natural killer–cell therapy led to an ongoing complete response at 15 months in Waldenstrom lymphoma.

Nogapendekin alfa inbakicept plus an immune checkpoint inhibitor generated absolute lymphocyte count increases in non–small cell lung cancer.

Adjuvant pembrolizumab did not improve RFS vs placebo in HCC following complete radiological response after surgical resection or local ablation.

Pumitamig/nab-paclitaxel produced responses in advanced TNBC in a phase 2 study, informing its further evaluation in the phase 3 ROSETTA Breast-01 trial.

CPI-008 received orphan drug designation from the FDA and EMA for margin detection of pancreatic cancer during surgery.

Orca-T plus allogeneic CAR T-cell therapy may represent a rational treatment approach in high-risk B-cell malignancies.

Obe-cel produced responses and low rates of high-grade CRS and ICANS in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Bezuclastinib normalized key bone marrow pathology in nonadvanced systemic mastocytosis.

Ceralasertib plus durvalumab did not improve overall survival vs docetaxel in previously treated advanced non–small cell lung cancer.

Orca-T given with reduced intensity conditioning led to robust myeloid/T-cell engraftment and low rates of acute GVHD in hematologic malignancies.

Passion to help individual patients fueled the career of Mark G. Kris, MD, in driving lung cancer research and management.

Adam Fox, MD, discusses the need for molecular profiling in non–small cell lung cancer and how these results factor into multidisciplinary planning.

Epcoritamab-based treatment yielded durable remissions in patients with follicular lymphoma, both as first-line induction and maintenance.

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

Varegacestat improved progression-free survival vs placebo in patients with progressing desmoid tumors.

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

The EMA recommended conditional marketing authorization for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS.

Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.

The FDA granted orphan drug designation to the B7-H3–targeted antibody-drug conjugate GSK’227 for small cell lung cancer.

T-DXd yielded iDFS improvements in HER2-positive early breast cancer with residual invasive disease, irrespective of HER2 expression of neoadjuvant chemotherapy type.

Myeloablative Orca-Q demonstrated efficacy and safety in high-risk hematologic malignancies.

GC012F/AZD0120 produced responses in high-risk, transplant-eligible multiple myeloma, as well as transplant-ineligible, newly diagnosed disease.

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations